Division Of Hematology And Oncology

Vanderbilt researchers found that that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional. Read More

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening. Read More

Vanderbilt reseach shows that resources for lung cancer screening programs increased the number of veterans screened. Read More

New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death. Read More

Vanderbilt researchers identified a critical role for IL-1beta signaling in leukemia cells with a certain mutation, suggesting this pathway may be a good target for novel treatments. Read More

A gene variant that lowers white blood cell levels and is common in individuals with African ancestry contributes to unnecessary bone marrow biopsies, according to a study published June 28 in JAMA Internal Medicine.  The findings, led by investigators at VUMC, are an example of how using genetic data could reduce a health disparity.  Read More

Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy. Read More

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level. Read More

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets. Read More

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients. Read More

Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report. Read More

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work Read More

A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer. Read More

The grant will support Mary Philip's research to develop an organoid model — a miniature cell model of a functioning organ — of the liver to enable three-dimensional observation of immune-cancer interactions at the single-cell level at the earliest stages of cancer development. Read More

W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer. Read More

With last week’s election of Lorraine Ware, MD, as vice president of the American Society for Clinical Investigation (ASCI), two faculty members of the Vanderbilt University School of Medicine are among the current officers of the elite physician-scientist honor society. Read More

Investigators at Vanderbilt-Ingram Cancer Center (VICC) and the Virginia Tech Carilion Research Institute (VTCRI) have revealed a gene mutation’s role in Von Hippel-Lindau syndrome, a genetically inherited disease which causes tumor growth in several organs. Read More

W. Kimryn Rathmell, MD, PhD, Cornelius A. Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt University Medical Center (VUMC), has been elected to the nominating committee for the American Society of Clinical Oncology (ASCO). Read More

A trio of Vanderbilt University scientists described their cutting-edge investigations of cellular dynamics and cancer treatment during last week’s Flexner Discovery Lecture. Read More

Vanderbilt-Ingram Cancer Center (VICC) will sponsor an educational conference for kidney cancer patients, survivors and family members Saturday, Sept. 9, 8 a.m. – 2 p.m., in the Preston Research Building, Suite 898. Read More